Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19

11/20 Late treatment study

Garibaldi et al., medRxiv, doi:10.1101/2020.11.19.20234153 (Preprint)
Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19

Source PDF Share Tweet

Retrospective 303 remdesivir patients and 303 matched controls showing significantly faster clinical improvement, and lower (but not statistically significant) mortality.

Garibaldi et al., 11/20/2020, retrospective, USA, North America, preprint, 10 authors.

risk of death, 20.0% lower, RR 0.80, p = 0.44, treatment 23 of 303 (7.6%), control 45 of 303 (14.9%), adjusted per study.

risk of no improvement at day 28, 35.0% lower, RR 0.65, p < 0.001, treatment 52 of 303 (17.2%), control 80 of 303 (26.4%), adjusted per study.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 29 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit